Episode 11: Why this is Gene Therapy's Moment with Kristin Viswanathan Wolff, Vice President, Market Access at bluebird bioEpisode 11: Why this is Gene Therapy's Moment with Kristin Viswanathan Wolff, Vice President, Market Access at bluebird bio
Healthscape
Kristin Wolff from Bluebird Bio shares insights on gene therapy's potential to transform healthcare, focusing on rare diseases and market access strategies.
31:38•30 May 2023
Gene Therapy: A New Era in Healthcare
Episode Overview
- Gene therapy is transitioning from niche to mainstream in healthcare.
- Bluebird Bio focuses on rare diseases but aims for broader applications.
- Collaboration across stakeholders is crucial for market success.
- Innovative payment models can mitigate risks for payers.
- Societal value of gene therapies extends beyond individual patients.
“The progress we've seen in gene therapy has given us enough time that we're ready to meet this moment.”
Imagine a world where gene therapy is no longer just a futuristic concept but a reality shaping the healthcare landscape today. In this episode of Healthscape, Kristin Viswanathan Wolff, Vice President of Market Access at bluebird bio, takes you on a journey through the exciting developments in gene therapy. From the historical roots of Bluebird Bio to the challenges and triumphs of bringing gene therapies to market, Kristin offers a comprehensive look at why this is gene therapy's moment.
Her career path, marked by a shift from clinical aspirations to impactful public policy work, provides fascinating insights into the multifaceted world of healthcare innovation. Gene therapy has been evolving from a niche curiosity to a mainstream medical tool, with Bluebird Bio at the forefront of this transformation. Kristin explains how Bluebird's focus on rare diseases is paving the way for broader applications that could potentially touch the lives of thousands.
The conversation explores the complexities of market access, collaboration across stakeholders, and the innovative strategies Bluebird employs to ensure patients receive these groundbreaking treatments. Kristin's reflections on collaboration highlight the importance of incremental progress in overcoming barriers in healthcare systems. She discusses how Bluebird Bio navigates payment models and reimbursement challenges, emphasising the need for performance-based contracts that mitigate risks for payers.
Her insights into the societal value of gene therapies prompt listeners to consider the broader impact on families and communities. If you're curious about how gene therapy is reshaping medicine and want to understand the intricacies of market access, this episode offers a wealth of information and inspiration. Dive into the conversation and discover why gene therapy is poised to revolutionise healthcare.
Do you want to link to this podcast?
Get the buttons here!
More From This Show
The latest episodes from the same podcast.
Related Episodes
Similar episodes from other shows in the catalogue.